Market Research Logo

Myocardial Ischemia - Pipeline Review, H2 2015

Myocardial Ischemia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Myocardial Ischemia - Pipeline Review, H2 2015’, provides an overview of the Myocardial Ischemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myocardial Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Ischemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Myocardial Ischemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Myocardial Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Myocardial Ischemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Myocardial Ischemia Overview
Therapeutics Development
Pipeline Products for Myocardial Ischemia - Overview
Pipeline Products for Myocardial Ischemia - Comparative Analysis
Myocardial Ischemia - Therapeutics under Development by Companies
Myocardial Ischemia - Therapeutics under Investigation by Universities/Institutes
Myocardial Ischemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Myocardial Ischemia - Products under Development by Companies
Myocardial Ischemia - Products under Investigation by Universities/Institutes
Myocardial Ischemia - Companies Involved in Therapeutics Development
Cellmid Limited
CoDa Therapeutics, Inc.
CohBar Inc.
Lixte Biotechnology Holdings, Inc.
Miltenyi Biotec GmbH
NoNO, Inc.
Nyken BV
Opsona Therapeutics Limited
Taxus Cardium Pharmaceuticals Group Inc.
ViroMed Co., Ltd.
Myocardial Ischemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Alda-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alferminogene tadenovec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AntimiR-199a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CMK-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EP-80317 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Ischemic Heart Failure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Humanin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LB-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NYK-1112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPN-305 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMC-6 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Protein for Myocardial Infarction and Critical Limb Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cardiovascular Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myocardial Ischemia - Recent Pipeline Updates
Myocardial Ischemia - Dormant Projects
Myocardial Ischemia - Discontinued Products
Myocardial Ischemia - Product Development Milestones
Featured News & Press Releases
May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City
Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology
Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention
Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy
May 18, 2012: New drug discovery collaborations with Queen Mary University of London launched
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Myocardial Ischemia, H2 2015
Number of Products under Development for Myocardial Ischemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Myocardial Ischemia - Pipeline by Cellmid Limited, H2 2015
Myocardial Ischemia - Pipeline by CoDa Therapeutics, Inc., H2 2015
Myocardial Ischemia - Pipeline by CohBar Inc., H2 2015
Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015
Myocardial Ischemia - Pipeline by Miltenyi Biotec GmbH, H2 2015
Myocardial Ischemia - Pipeline by NoNO, Inc., H2 2015
Myocardial Ischemia - Pipeline by Nyken BV, H2 2015
Myocardial Ischemia - Pipeline by Opsona Therapeutics Limited, H2 2015
Myocardial Ischemia - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2015
Myocardial Ischemia - Pipeline by ViroMed Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Myocardial Ischemia Therapeutics - Recent Pipeline Updates, H2 2015
Myocardial Ischemia - Dormant Projects, H2 2015
Myocardial Ischemia - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Myocardial Ischemia, H2 2015
Number of Products under Development for Myocardial Ischemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report